

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 24 MAY 2024

The Board hereby announces that all the proposed resolutions as set out in the AGM Notice dated 29 April 2024 were duly passed by the Shareholders at the AGM held on 24 May 2024 by way of poll.

Reference is made to the circular (the “**Circular**”) of Immunotech Biopharm Ltd (the “**Company**”) and the notice (the “**AGM Notice**”) of the Annual General Meeting (the “**AGM**”) of the Company both dated 29 April 2024. Unless otherwise defined, the terms used in this announcement shall have the same meanings as those defined in the Circular and the AGM Notice.

POLL RESULTS OF THE AGM

As at the date of the AGM, the number of Shares in issue was 514,584,000 Shares, which was the total number of Shares entitling the shareholders to attend and vote for or against all the resolutions proposed at the AGM. There were no Shareholders who were entitled to attend the AGM but were required to abstain from voting in favour of any of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required to abstain from voting on any of the resolutions proposed at the AGM. No Shareholder was entitled to attend and vote only against any of the resolutions proposed at the AGM. No parties had stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

The Board is pleased to announce that all the proposed resolutions as set out in the AGM Notice were duly passed by the Shareholders by way of poll at the AGM. The poll results of all the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS*		Number of votes cast and approximate percentage of total number of votes	
		For	Against
1.	To consider and adopt the audited consolidated financial statements of the Company and the reports of the Directors and the auditor for the year ended 31 December 2023.	299,748,257 100.00%	0 0.00%
2(a).	To re-elect Mr Tan Zheng as an executive Director.	299,748,257 100.00%	0 0.00%
2(b).	To re-elect Dr Wang Yu as an executive Director.	299,748,257 100.00%	0 0.00%
2(c).	To re-elect Mr Tao Ran as a non-executive Director.	299,748,257 100.00%	0 0.00%
2(d).	To re-elect Mr Wang Donghu as a non-executive Director.	299,748,257 100.00%	0 0.00%
3.	To authorise the Board to fix the Directors' remuneration.	299,748,257 100.00%	0 0.00%
4.	To re-appoint Deloitte Touche Tohmatsu as auditor and to authorise the Board to fix their remuneration.	299,748,257 100.00%	0 0.00%
5.	To grant a general mandate to the Directors to allot, issue and deal with new shares of the Company with an aggregate number of not exceeding 20% of the total number of shares of the Company in issue as at the date of passing of the relevant resolution at the AGM.	299,715,257 99.99%	33,000 0.01%
6.	To grant a general mandate to the Directors to repurchase the Company's shares with a total number of not more than 10% of total number of shares of the Company in issue at the date of passing the relevant resolution at the AGM.	299,748,257 100.00%	0 0.00%

ORDINARY RESOLUTIONS*		Number of votes cast and approximate percentage of total number of votes	
		For	Against
7.	To extend the general mandate granted to the Directors under resolution 5 by an amount representing the aggregate number of the Company's shares repurchased by the Company under resolution 6, provided that such amount shall not exceed 10% of the total number of shares of the Company in issue as at the date of passing of the relevant resolution at the AGM.	299,715,257 99.99%	33,000 0.01%
SPECIAL RESOLUTION*		Number of votes cast and approximate percentage of total number of votes	
		For	Against
8	To approve (a) the proposed amendments (the " Proposed Amendments ") to the third amended and restated memorandum of association and articles of association of the Company (the " Existing Memorandum and Articles of Association ") as set out in Appendix III to the circular of the Company dated 29 April 2024; (b) the adoption of the fourth amended and restated memorandum and articles of association of the Company incorporating the Proposed Amendments in substitution for and to the exclusion of the Existing Memorandum and Articles of Association; and (c) any Director, secretary and/or registered office provider of the Company be and is hereby authorized to do all such acts as may be necessary or expedient in connection to the Company's adoption of the fourth amended and restated memorandum and articles of association and to make relevant registrations and filings in accordance with the requirements of the applicable laws in the Cayman Islands and Hong Kong.	299,748,257 100.00%	0 0.00%

* *The full text of the above resolutions is set out in the AGM Notice.*

Computershare Hong Kong Investor Services Limited, the Company's Hong Kong Branch Share Registrar, acted as the scrutineer at the AGM for the purpose of vote-taking. As more than 50% of the votes were cast in favour of each of the above resolutions no. 1 to 7, all the above resolutions were duly passed as ordinary resolutions at the AGM. As not less than three-fourths of the votes were cast in favour of the resolution no. 8, the resolution was duly passed as a special resolution at the AGM.

All of the Directors, namely Mr Tan Zheng, Dr Wang Yu, Mr Tao Ran, Mr Wang Ruihua, Mr Yang Fan, Mr Wang Donghu, Professor Wang Yingdian, Mr Ng Chi Ki and Ms Peng Sujiu, attended the AGM either in person or via electronics means.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 24 May 2024

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu as executive Director, Mr Tao Ran, Mr Wang Ruihua, Mr Yang Fan and Mr Wang Donghu as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.